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Abstract Interleukin-6 (IL-6) has emerged as a potent
biomarker for depression as its elevated plasma levels in
patients with clinical depression have been confirmed by
meta-analyses. Increased plasma IL-6 concentration was
associated with various psychological stress factors and
physical disorders accompanied by pain. Another modu-
lator of the IL-6 level is rs1800795, a promoter polymor-
phism in the IL-6 gene which is able to influence its
expression rate. Therefore, we examined in a Hungarian
population sample of 1053 volunteers with European ori-
gins if rs1800795 polymorphism can affect depression
symptoms measured by Zung Self-rating Depression Scale
(ZSDS), and Brief Symptom Inventory (BSI). We also
investigated the interactions of the polymorphism with
reported painful physical conditions and Recent Negative
Life Events (RLE) measured by the List of Life Threat-
ening Experiences. Rs1800795 significantly interacted with
both RLE and painful condition on depressive symptoms
measured by ZSDS and BSI using different heritability
models, while no main effects of the polymorphism were
identified. After correction for multiple testing only the
rs1800795 9 RLE interaction effect (recessive model)
remained significant on the BSI score, while both RLE and
painful conditions significantly interacted on the ZSDS. In
conclusion, the functional IL-6 rs1800795 polymorphism
in interaction with various stress factors increases the risk
of depression and has a greater impact on symptoms
measured by the ZSDS. Thus, IL-6 and other cytokines
may be more relevant in the development of somatic
symptoms compared to affective signs of depression,
delineating a specific genotype–phenotype relationship in
this heterogeneous disorder.
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Introduction
Apart from the evident involvement of monoamine neu-
rotransmitter disturbances in depression, pro-inflammatory
cytokine levels were repeatedly reported to be increased in
depressed individuals compared to control subjects with
meta-analyses also supporting this observation (Dowlati
et al. 2010; Howren et al. 2009). In addition, externally
administered cytokines are also able to cause depressive
symptoms in animal models (Dunn et al. 2005), and
depression was consistently reported as a side effect of
interferon (IFN) treatment in human subjects (Bull et al.
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2009; Kovacs et al. 2015). The risk of developing
depression during IFN treatment was found to be depen-
dent on a functional polymorphism in the interleukin-6 (IL-
6) gene, rs1800795 (Udina et al. 2013). This polymorphism
alters transcription rates of the IL-6 gene in HeLA cells
especially after stimulation with interleukin-1 (IL-1) or
lipopolysaccharide (LPS) (Fishman et al. 1998). However,
the more recent reports were inconsistent about which
allele of the polymorphism causes higher expression rates
(Fife et al. 2005; Kelberman et al. 2004; Terry et al. 2000).
In spite of these controversies, the involvement of the
rs1800795 polymorphism in the development of various
disorders such as Alzheimer’s disease (Faltraco et al.
2003), schizophrenia (Zakharyan et al. 2012), and cerebral
palsy (Wu et al. 2011) was also supported.
Regarding the pathophysiology of depression, it has
been proposed that environmental factors—mainly stress—
can exert their depressogenic effects through neuroin-
flammatory signalling mechanisms (McEwen 2000), and
stress-induced depressive conditions were associated with
significantly higher IL-6 levels (Bob et al. 2010). IL-6 was
also elevated in subjects exposed to various depression-
related stressful circumstances like childhood abuse, low
socioeconomic status, negative social interactions, or par-
ental loss (Slavich and Irwin 2014).
Apart from the relatively new findings about IL-6, stress
and depression, IL-6 is a confirmed modulator of pain
processing (De Jongh et al. 2003). In animal models IL-6
mediated neuropathic pain development (Arruda et al.
1998), C-fiber sensitization to mechanical stimuli in joint
pain (Brenn et al. 2007), and enhanced migraine-like
allodynia (Yan et al. 2012). Moreover, in human subjects
IL-6 receptor inhibition with monoclonal antibodies
showed greater therapeutic value against painful symptoms
of rheumatoid arthritis compared to placebo (Smolen et al.
2008). Furthermore, IL-6 influenced the development of
depression in fibromyalgia patients (Wallace et al. 2001),
and a meta-analysis also demonstrated elevated IL-6 levels
associated with the prevalence of depression, and inversely
correlated with survival rates in patients with malignant
tumors (Illman et al. 2005). The co-occurrence of these
usually painful medical conditions and depression has been
proposed to have a common neuroinflammatory aetiologi-
cal background with the involvement of IL-6 and other
cytokines (Walker et al. 2014).
Differences in the emergence of depressive symptoms
during cytokine therapy was observed suggesting a primer
involvement of cytokines in ‘‘somatic symptoms’’ (e.g.,
fatigue, loss of appetite, and increased pain) rather than
‘‘emotional symptoms’’ of depression (Loftis et al. 2013).
This secondary effect on emotional aspects were proposed
to be the result of tryptophan depletion caused by the pri-
mary loss of appetite, and the activation of indolamine-2,3-
dioxygenase (IDO) which is the first enzyme of the
kynurenine pathway, degrading tryptophan to kynurenic
acid, and decreasing tryptophan levels available for sero-
tonin synthesis (Capuron et al. 2002). Therefore, it seems
to be logical to expect a slightly different symptom profile
during cytokine-mediated depression.
In our study, we hypothesized that rs1800795 can
interact with both physical and psychological stress factors
influencing the somatic and affective depressive symptoms
differently. Therefore, we tested the effect of rs1800795
polymorphisms on depressive symptom scores by two
different measures, namely by the Brief Symptom Inven-
tory (BSI), and by the Zung Self-Rating Depression Scale
(ZSDS), from which the latter one has more emphasis on
somatic symptoms (Gonda et al. 2005). We also examined
the polymorphism’s interaction with Recent Negative Life
events (RLE) and Pain Background (PBGR) information
reported by the subjects.
Methods
Population
Collection of phenotypic and genetic data was carried out
during the New Molecules in Mood Disorders (NewMood)
project (Sixth Framework Program of the European Union
LHSM-CT-2004-503474). 1093 volunteers provided
genetic samples and phenotypic information through
completing questionnaire packs delivered by postal service
or personally in Budapest, Hungary. The volunteers were
recruited through advertisement and general practices in
universities and community-based populations (Lazary
et al. 2008). Signing the official consent form was
mandatory before participants entered the study. Our study
was designed and performed in accordance with the dec-
laration of Helsinki, and was approved by the local ethic
committees. The statistical analysis of the population
sample required exclusion of blood relatives obviously not
meeting the criteria of independence from a genetic per-
spective. We also excluded non-white ethnic origin indi-
viduals who were represented only by eight people (1
Asian-Indian, 5 mixed, and 2 ‘‘other’’), to avoid stratifi-
cation bias.
Phenotypes
We used two different outcome variables reflecting current
depression in the analysis: the continuous weighted
dimension scores of the depression and additional items
subscales of the Brief Symptom (Derogatis and Melisaratos
1983) and of the Zung Self-Rating Depression Scale
(ZSDS) (Zung et al. 1965).
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Recent Life Events (RLE) were assessed by The List of
Life Threatening Experiences questionnaire (Brugha et al.
1985) but only included the events that happened in the
previous year. In the analysis, we used the sum of reported
stressful life events in the past year. The Pain Background
(PBGR) variable was derived from our background ques-
tionnaire, including the items which describe painful con-
ditions such as migraine, back pain, or rheumatologic
disorders. Pain Background was considered as a categorical
variable in our analyses, with subjects reporting no painful
conditions falling into category 1 and subjects reporting
one or more painful condition falling into category 2.
Genotypes
For genotype analysis, participants collected their own
buccal mucosa cells with cytology brushes provided to
them. DNA was extracted by a validated method (Freeman
et al. 2003). The polymorphism rs1800795 of the IL-6 gene
was genotyped with the Sequenom MassARRAY tech-
nology (Sequenom, San Diego).
Statistical analysis
PLINK 1.0.7 (http://pngu.mgh.harvard.edu/purcell/plink)
and IBM SPSS 20.0 for Windows were used for all sta-
tistical analyses performed including linear regression,
Hardy–Weinberg equilibrium determination, and Pearson
correlation analysis. In the linear regression analyses age
and gender of the subjects were always used as covariates.
Nominal significance level was set at p = 0.05. Bonferroni
correction for multiple testing was used to avoid bias,
which reduced significance level to p = 2.78 9 10-3.
Power calculations with Quanto program (http://biostats.
usc.edu/Quanto.html) using the mean and standard devia-
tion values from Table 1, and assuming the main effect of
the polymorphism to explain R2 = 1 % of the variance in
both ZSDS and BSI depression score, indicated a 83.6 %
power to detect these effects. With the same settings but
assuming RLE-genetic polymorphism interaction indicated
84.3 % power to detect effects on our outcome variables.
Results
The examined population sample contains only European
white subjects from independent families (siblings and
immediate blood relatives were excluded). Out of 1053
participants, 998 provided good quality DNA and were
genotyped with a call rate of 93.3 %. Due to missing
phenotypic data, our analysis was carried out on 862 sub-
jects in the case of BSI depression score, and 859 subjects
in the case of ZSDS score. In our population sample, the
number of female participants exceeded more than twofold
the male participants’ number. The mean age of the pop-
ulation was 31.2 years (Table 1). There was a significant
correlation between our two outcome variables the ZSDS
and BSI depression scores (Pearson correlation R = 0.637,
p\ 0.001). The frequency of the minor (C) allele in our
sample was 0.43. In contrast, the frequency of the C allele
according to HAPMAP in central European population was
0.535. The rs1800795 SNP was in Hardy–Weinberg equi-
librium in the sample (p = 1.0).
At nominal significance level, no main effect of the
rs1800795 polymorphism was detected on either of our
outcome variables. On the other hand, rs1800795 in
interaction with RLE and assuming an additive or recessive
heritability model showed significant associations both
with ZSDS and BSI depression scores (Figs. 1, 2.) The
interaction of rs1800795 with PBGR was also significant
assuming additive and dominant heritability in the case of
BSI depression score, and assuming all three heritability
models (additive, dominant, recessive) in the case of ZSDS
score (Figs. 3, 4). After correcting for multiple testing
using Bonferroni method, the BSI depression score was
only affected significantly by the rs1800795 9 RLE
interaction using a recessive model, while in the case of
ZSDS score both additive and recessive models of
rs1800795 9 RLE interaction remained significant, and
the rs1800795 9 PBGR interaction assuming additive and
dominant models also survived the correction (Table 2).
Table 1 The phenotypic variables of the population sample and their
descriptive statistics
Total N Male Female
Gender 1053 320 733
Painful conditions 140 45 95
Total
N
Minimum Maximum Mean Standard
deviation












1048 0 8 1.083 1.17
BSI depression score: continuous weighted dimension score of Brief
Symptom Inventory’s items for depression
Zung depression score: continuous weighted dimension score of Zung
Self-Rating Depression Scale
Recent Life Events: Sum of items of List of Life Threatening
Experiences happening in the previous year
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Discussion
Based on our results, the rs1800795 polymorphism, situ-
ated within the promoter region of the IL-6 gene signifi-
cantly interacted with both psychological and physical
stress factors on depressive symptoms. In addition, this
interaction effect was stronger on depressive symptoms
measured by the Zung Self-Rating Depression Scale
compared those measured by the Brief Symptom Inventory
suggesting that IL-6 plays a more important role in the
development of somatic depressive symptoms than emo-
tional-cognitive symptoms.
Somatic and psychological stress factor interactions
The differences between the intensity of the RLE and
PBGR interactions in our sample were not relevant, sug-


























Fig. 1 Interaction between rs1800795 and recent life events influ-
ences Brief symptom inventory depression scores. Subjects with the
most Recent Life Stress (RLE) exposure and homozygote minor allele
showed significantly more depression symptoms measured by Brief
Symptom Inventory (BSI) compared to other groups. Significant
interactions were found using additive (p = 0.015) and recessive

























Fig. 2 Interaction between rs1800795 and recent life events influ-
ences Zung Self-rating Depression Scale scores. Severity of life stress
in the previous year (RLE) influenced rs1800795 polymorphism’s
effect on depression symptoms measured by Zung Self-rating
Depression Scale (ZSDS). CC genotype carriers achieved signifi-
cantly higher scores in the most exposed subgroup; however, GG
carriers scored slightly higher when in the mildly exposed subgroup.
There is no evident difference in the least exposed subgroup.
Significant interactions were found using additive
(p = 1.17 9 10-3), and recessive (p = 2.86 9 10-5) models in

























Fig. 3 Interaction between rs1800795 and painful conditions influ-
ences Brief Symptom Inventory depression scores. Rs1800795
polymorphism in interaction with painful conditions elevates depres-
sion symptom levels measured by the Brief Symptom Inventory (BSI)
in minor (C) allele carriers. Subjects in category one did not report
any painful disorders, while subject group marked with two reported
migraine, rheumatoid arthritis, back pain or other painful disorders.
Significant interactions were found using additive
(p = 2.96 9 10-3), and dominant (p = 4.78 9 10-3) models in
























Fig. 4 Interaction between rs1800795 and painful conditions influ-
ences Zung Self-rating Depression Scale scores. Subjects in category
marked one did not report any painful conditions. Pain background
category two represents exposure to painful medical conditions such
as rheumatoid arthritis, migraine, or low-back pain. These conditions
elevated Zung Self-rating Depression Scale Scores in minor (C) allele
carriers of the polymorphism. Significant interactions were found
using additive (p = 7.42 9 10-4), dominant (p = 2.12 9 10-3), and
recessive (p = 0.021) models in linear regression analyses with
PLINK 1.0.7 program
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of depressive symptoms. However, it is interesting that
RLE interactions preferred additive and recessive models,
while PBGR interactions preferred additive and dominant
models. Thus, painful conditions might be able to induce
depression in CG heterozygotes, where the expression rate
just slightly changed, while only homozygous CC carrier
status causes vulnerability to other life stressors, where the
IL-6 expression rates changes more considerably. Based on
the previous studies which investigated plasma IL-6 levels
in depression and during stressful experiences we can
assume that our risk variant, namely the C allele, might
induce over expression of IL-6 and thus increase depressive
symptom scores (Howren et al. 2009).
Initially the major allele (G) of rs1800795 was found to
be the higher IL-6 expressing variant (Fishman et al. 1998).
This SNP is located at the promoter region of the IL-6 gene
and changes its transcription rate by modulating the tran-
scriptional factor binding capability of the promoter
sequence (http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/
snpfunc.cgi). Recently it has been also suggested that this
polymorphism is part of a functional haplotype, exerting its
effect in a non-independent manner on gene expression
(Fife et al. 2005). Although unfortunately we only mea-
sured rs1800795 and no other haplotype tagging SNPs in
this region these recent findings might explain why we
found the minor C allele to be the risk variant on depres-
sion in interaction with both of our stress factors.
Differences in the sensitivity of outcome phenotype
measures
Generally, we found ZSDS more suitable for the detection
of the IL-6 polymorphism’s effect on mood disturbances.
The differences in significant hit numbers were minimal on
nominal significance level; however, after correction for
multiple testing with Bonferroni method, only one signif-
icant hit remained in the BSI depression group, while five
of them survived the correction in the ZSDS group. The
differences indicate that somatic symptoms of depression,
captured more expansively by ZSDS compared to BSI
scale are more responsive to the interactions of rs1800795
polymorphism. ZSDS has a well-established somatic sub-
scale (Gonda et al. 2005; Kitamura et al. 2004) and was
also more sensitive to assess depression risk in spinal cord
injury patients compared to BSI depression scale (Tate
et al. 1993). Moreover, changes in cytokine expression
profile with increased ZSDS score were demonstrated in
depressed patients with significant differences in childhood
trauma-exposed versus non-exposed groups of patients,
suggesting that symptoms measured by the ZSDS reflect
psychological stress-induced cytokine-mediated patholog-
ical processes (Lu et al. 2013). In summary, our results
concerning the rs1800795 polymorphism strengthen earlier
findings which support that ZSDS is a superior tool for
measuring cytokine-mediated depression when psycho-
logical or physical interacting factors were present.
Psychobiological implications of the results
Since IL-6 has a prominent role in cognitive function
(McAfoose and Baune 2009), and in the internalization of
various stress types (Slavich and Irwin 2014), it is possible
that IL-6 is involved in depression-specific changes of the
brain structure. Most studies reported a neurodegenerative
effect of IL-6 (Marsland et al. 2008; Vallieres et al. 2002),
however, the earlier findings assigned neuroprotective
features to IL-6 (Tilg et al. 1997; Wagner 1996). The
neuroprotective function is supported by an MRI study
Table 2 Effect of the rs1800795 polymorphism and its interaction with recent life events and painful conditions on depression scores measured
by the BSI and ZSDS
ADD DOM REC
p value b SD p value b SD p value b SD
BSI Depression score
Main effect 0.315 0.035 0.034 0.746 0.017 0.052 0.156 0.088 0.062
RLE interaction 0.015 0.027 0.013 0.348 0.039 0.041 1.19 3 1023 0.158 0.049
PBGR interaction 2.96 3 1023 0.307 0.103 4.78 3 1023 0.422 0.149 0.06413 0.346 0.186
ZSDS score
Main effect 0.971 0.0005 0.014 0.571 -0.01 0.021 0.459 0.018 0.025
RLE interaction 1.17 3 1023 0.036 0.011 0.167 0.023 0.017 2.86 3 1025 0.085 0.02
PBGR interaction 7.42 3 1024 0.139 0.041 2.12 3 1023 0.186 0.06 0.021 0.171 0.074
Significant interactions are highlighted in bold (p\ 0.05)
BSI depression score was measured by the Brief Symptom Inventory depression subscale. ZSDS score was measured by Zung Self-Rating
Depression Scale. RLE: Recent life events measured by List of Life Threatening experiences, PBGR: Painful conditions measured by our
background questionnaire. SD standard deviation, ADD, DOM, REC additive, dominant, recessive heritability models
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which reported increased hippocampal gray matter vol-
umes in carriers of the G allele of rs1800795 polymor-
phism (Baune et al. 2012). As mentioned above there is a
well-established hypothesis that environmental stress fac-
tors can affect depressive states by neuroinflammatory
mechanisms such as hypothalamus–pituitary–adrenal
(HPA) axis hyperactivity (Mokrani et al. 1997), or acti-
vation of the kynurenine pathway (Miura et al. 2008).
However, based on the available literature and our results,
IL-6 seems to have a two-faced effect on depression phe-
notype. Even though it was found to be elevated in the
peripheral blood serum samples of depressed patients by a
meta-analysis (Dowlati et al. 2010), it is necessary for
healthy brain development and for synaptic plasticity
(Molina-Holgado and Molina-Holgado 2010). Considering
these findings and also that rs1800795 is probably exerting
its effect on IL-6 expression rate through a functional
haplotype rather than alone (Fife et al. 2005), it seems
unlikely to find either allele of the rs1800795 polymor-
phism to be exclusively associated with a depression
phenotype.
Limitations
In the analysis we could only examine the effect of the
rs1800795 polymorphism; however, it has been proposed
to be part of a functional haplotype (Fife et al. 2005). The
gender distribution of our population sample was not bal-
anced and also the sample size is considered relatively
small nowadays. Our analysis considered the interaction
effect of rs1800795 with painful conditions and recent
negative life events, although it is possible that many other
factors exist which can modulate the effect of rs1800795,
such as social support, childhood adversity, or socioeco-
nomic variables. Also some of the findings did not meet the
criterion of Bonferroni corrected significance threshold; so
further studies are required to confirm the validity of them.
We measured the outcome and interacting variables by
self-report questionnaires which can produce biased
results.
Conclusions
Rs1800795 polymorphism in interaction with both physical
and psychological stress factors influenced depressive
symptom phenotypes measured by the Zung Self-Rating
Depression Scale and the Brief Symptom Inventory, but no
main effect of the polymorphism was detectable. This
suggests that further investigations should also consider
including interacting factors, whether they are painful
disorders or negative life events, when they examine the
effect of rs1800795 on depression. Our study also supports
the hypothesis that cytokines affect physical and somatic
aspects of depression to a greater degree than the emotional
aspects, therefore using the proper outcome measure such
as the ZSDS might significantly improve the success rates
of further studies investigating the effect of cytokines on
depression.
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